P10.10 Trends in Treatment Patterns and Survival in Advanced NSCLC Patients Treated at Frankfurt University Hospital in 2012–2018

Immuno-oncology (IO) therapy has improved outcomes for patients with advanced non-small cell lung cancer (NSCLC) versus chemotherapy in clinical trials. In Germany, immune checkpoint inhibitors have been used clinically since 2015 for patients with advanced/metastatic NSCLC without ALK/EGFR aberrations. As part of I-O Optimise, a multinational research program utilizing real-world data on thoracic malignancies, we describe the evolution of treatment patterns and overall survival (OS) for patients with advanced NSCLC treated at Frankfurt University Hospital (FUH) following the availability of IO therapies.